The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.
An economic evaluation of reducing the age threshold for routine influenza vaccination in Spain from 65 to 50 years was performed. A probabilistic model was used to compare a policy based on a recommendation to vaccinate all adults aged 50-64 with the existing vaccination policy for that age group, during interpandemic periods. Two perspectives were considered: third-party payer (TPP) and societal. Model inputs were obtained primarily from the published literature and validated through expert opinion. From TPP perspective, incremental cost-effectiveness ratios were estimated at euro14,919 per quality-adjusted life-year (QALY) gained and euro9731 per life-year gained. From societal perspective, the corresponding results were euro4149 per QALY and euro2706 per life-year gained. Extending routine influenza vaccination to people over 50 years of age is likely to be cost-effective.
Aballéa
Samuel
S
i3 Innovus, Uxbridge, UK. saballea@i3innovus.com
De Juanes
Jose Ramón
JR
Barbieri
Marco
M
Martin
Monique
M
Chancellor
Jeremy
J
Oyagüez
Itziar
I
Verwee
Bertrand
B
Largeron
Nathalie
N
D003362:Cost-Benefit Analysis; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000191:economics* / Q000276:immunology; D007251:Influenza, Human / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*; D008875:Middle Aged; D018803:Models, Economic; D019057:Quality-Adjusted Life Years; D013030:Spain / Q000453:epidemiology; D014611:Vaccination / Q000191:economics
D007252:Influenza Vaccines